5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $33M | -$53M | 99.4% | -154.7% | -$49M | $15M | $35M |
| 2024 | $3M | -$61M | 92.3% | -2437.5% | -$51M | $15M | $22M |
| 2023 | $3M | -$49M | 93.3% | -1866.2% | -$46M | — | $31M |
| 2022 | $4M | -$34M | 94.0% | -924.3% | -$30M | — | $20M |
| 2021 | — | -$378753 | — | — | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $110000 | -$21M | 70.9% | -20069.1% | -$22M | $15M | $28M |
| Dec '25 | $31M | $6M | 99.8% | 21.8% | -$2M | $15M | $35M |
| Sep '25 | $861000 | -$21M | 94.3% | -2359.2% | -$15M | $15M | $42M |
| Jun '25 | $836000 | -$19M | 94.5% | -2311.8% | -$16M | $15M | $19M |
| Mar '25 | $868000 | -$19M | 94.9% | -2179.8% | -$17M | $15M | $18M |
| Dec '24 | $253000 | -$16M | 77.1% | -6591.7% | -$14M | $15M | $22M |
| Sep '24 | $987000 | -$15M | 93.1% | -1655.7% | -$14M | — | $26M |
| Jun '24 | $778000 | -$16M | 94.3% | -2167.0% | -$10M | — | $24M |
| Mar '24 | $620000 | -$13M | 94.5% | -2326.3% | -$13M | — | $23M |
| Dec '23 | $262000 | -$13M | 82.1% | -4763.7% | -$11M | — | $31M |
| Sep '23 | $419000 | -$13M | 90.2% | -3466.3% | -$10M | $10M | $19M |
| Jun '23 | $915000 | -$12M | 94.1% | -1416.0% | -$11M | $10M | $16M |
| Mar '23 | $1M | -$11M | 96.2% | -991.8% | -$14M | — | $19M |
| Dec '22 | $1M | -$10M | 95.2% | -891.0% | -$9M | — | $20M |
| Sep '22 | $1M | -$10M | 95.2% | -865.6% | -$7M | — | $735217 |
| Jun '22 | $401000 | -$8M | 85.0% | -1903.7% | -$8M | — | $1M |
| Mar '22 | $866000 | -$6M | 95.2% | -592.1% | -$5M | — | $1M |
| Dec '21 | — | -$88011 | — | — | — | — | $2M |
| Sep '21 | — | -$90411 | — | — | — | — | $2M |
| Jun '21 | — | -$92329 | — | — | — | — | $2M |
How the market has priced OBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, Orchestra BioMed Holdings, Inc.'s revenue has grown 111.6% per year. These are computed facts, not advice.
As of FY2025, Orchestra BioMed Holdings, Inc. reported $15M of total debt against $35M of cash.
In FY2025, gross margin was 99.4%, operating margin -154.7%, and net margin -157.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.